These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 38545126)

  • 1. CRISPR, CAR-T, and NK: Current applications and future perspectives.
    Khoshandam M; Soltaninejad H; Hamidieh AA; Hosseinkhani S
    Genes Dis; 2024 Jul; 11(4):101121. PubMed ID: 38545126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing.
    Dimitri A; Herbst F; Fraietta JA
    Mol Cancer; 2022 Mar; 21(1):78. PubMed ID: 35303871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Innovative Strategies of Reprogramming Immune System Cells by Targeting CRISPR/Cas9-Based Genome-Editing Tools: A New Era of Cancer Management.
    Allemailem KS; Alsahli MA; Almatroudi A; Alrumaihi F; Al Abdulmonem W; Moawad AA; Alwanian WM; Almansour NM; Rahmani AH; Khan AA
    Int J Nanomedicine; 2023; 18():5531-5559. PubMed ID: 37795042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of CRISPR/Cas9 System and CAR-T Cell Therapy: A New Era for Refractory and Relapsed Hematological Malignancies.
    Hu KJ; Yin ETS; Hu YX; Huang H
    Curr Med Sci; 2021 Jun; 41(3):420-430. PubMed ID: 34218353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strengthening the CAR-T cell therapeutic application using CRISPR/Cas9 technology.
    Sadeqi Nezhad M; Yazdanifar M; Abdollahpour-Alitappeh M; Sattari A; Seifalian A; Bagheri N
    Biotechnol Bioeng; 2021 Oct; 118(10):3691-3705. PubMed ID: 34241908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging CRISPR/Cas9 applications for T-cell gene editing.
    Preece R; Georgiadis C
    Emerg Top Life Sci; 2019 May; 3(3):261-275. PubMed ID: 33523139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CAR-T-Cell-Based Cancer Immunotherapies: Potentials, Limitations, and Future Prospects.
    Choudhery MS; Arif T; Mahmood R; Harris DT
    J Clin Med; 2024 May; 13(11):. PubMed ID: 38892913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Explorations of CRISPR/Cas9 for improving the long-term efficacy of universal CAR-T cells in tumor immunotherapy.
    Naeem M; Hazafa A; Bano N; Ali R; Farooq M; Razak SIA; Lee TY; Devaraj S
    Life Sci; 2023 Mar; 316():121409. PubMed ID: 36681183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The application of CRISPR-Cas9 genome editing tool in cancer immunotherapy.
    Wu HY; Cao CY
    Brief Funct Genomics; 2019 Mar; 18(2):129-132. PubMed ID: 29579146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A deep insight into CRISPR/Cas9 application in CAR-T cell-based tumor immunotherapies.
    Razeghian E; Nasution MKM; Rahman HS; Gardanova ZR; Abdelbasset WK; Aravindhan S; Bokov DO; Suksatan W; Nakhaei P; Shariatzadeh S; Marofi F; Yazdanifar M; Shamlou S; Motavalli R; Khiavi FM
    Stem Cell Res Ther; 2021 Jul; 12(1):428. PubMed ID: 34321099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic reprogramming for NK cell cancer immunotherapy with CRISPR/Cas9.
    Afolabi LO; Adeshakin AO; Sani MM; Bi J; Wan X
    Immunology; 2019 Oct; 158(2):63-69. PubMed ID: 31315144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment.
    Mollanoori H; Shahraki H; Rahmati Y; Teimourian S
    Hum Immunol; 2018 Dec; 79(12):876-882. PubMed ID: 30261221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Applications and explorations of CRISPR/Cas9 in CAR T-cell therapy.
    Li C; Mei H; Hu Y
    Brief Funct Genomics; 2020 May; 19(3):175-182. PubMed ID: 31950135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CRISPR Gene Editing of Human Primary NK and T Cells for Cancer Immunotherapy.
    Elmas E; Saljoughian N; de Souza Fernandes Pereira M; Tullius BP; Sorathia K; Nakkula RJ; Lee DA; Naeimi Kararoudi M
    Front Oncol; 2022; 12():834002. PubMed ID: 35449580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CRISPR/Cas9 Gene-Editing in Cancer Immunotherapy: Promoting the Present Revolution in Cancer Therapy and Exploring More.
    Ou X; Ma Q; Yin W; Ma X; He Z
    Front Cell Dev Biol; 2021; 9():674467. PubMed ID: 34095145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unleashing the Therapeutic Potential of CAR-T Cell Therapy Using Gene-Editing Technologies.
    Jung IY; Lee J
    Mol Cells; 2018 Aug; 41(8):717-723. PubMed ID: 30110720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novelty in improvement of CAR T cell-based immunotherapy with the aid of CRISPR system.
    Hajifathali A; Lasemi MV; Mehravar M; Moshari MR; Alizadeh AM; Roshandel E
    Hematol Transfus Cell Ther; 2024; 46(1):58-66. PubMed ID: 37451978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advancing chimeric antigen receptor T cell therapy with CRISPR/Cas9.
    Ren J; Zhao Y
    Protein Cell; 2017 Sep; 8(9):634-643. PubMed ID: 28434148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long Terminal Repeat CRISPR-CAR-Coupled "Universal" T Cells Mediate Potent Anti-leukemic Effects.
    Georgiadis C; Preece R; Nickolay L; Etuk A; Petrova A; Ladon D; Danyi A; Humphryes-Kirilov N; Ajetunmobi A; Kim D; Kim JS; Qasim W
    Mol Ther; 2018 May; 26(5):1215-1227. PubMed ID: 29605708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CRISPR/Cas-based CAR-T cells: production and application.
    Song P; Zhang Q; Xu Z; Shi Y; Jing R; Luo D
    Biomark Res; 2024 May; 12(1):54. PubMed ID: 38816881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.